Literature DB >> 3083889

Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.

R Pannell, V Gurewich.   

Abstract

Highly purified pro-urokinase (pro-UK) or single-chain urokinase-type plasminogen activator (scu-PA) was treated with diisopropylfluorophosphate (1 mmol/L) to eliminate traces of two-chain UK activity. This preparation was found to retain a low activity against a chromogenic substrate (S2444), equivalent to 0.1% to 0.5% of the activity of its plasmin-activated derivative. Evidence is presented that the intrinsic activity of pro-UK (scu-PA) was sufficient to activate plasminogen on a fibrin plate or in buffer and was far more reactive against Lys-plasminogen than against Glu-plasminogen. The relative resistance of Glu-plasminogen to activation was overcome by the addition of lysine (25 mmol/L) to the reaction mixture. By contrast, in plasma, pro-UK (scu-PA) was stable and nonreactive for greater than 72 hours when incubated (37 degrees C). Pro-UK (scu-PA) did not form sodium dodecyl sulfate-stable inhibitor complexes, whereas complexation occurred rapidly with UK. Only at high concentrations of pro-UK (scu-PA) (greater than or equal to 250 IU/mL) did plasminogen activation in plasma occur. The relative inertness of pro-UK (scu-PA) in plasma, in contrast to its low-grade enzymatic activity in buffer, was attributed to the effect of inhibitors. The addition of EDTA or the removal of divalent cations by dialysis was associated with a lower threshold for nonspecific plasminogen activation by pro-UK (scu-PA) in plasma. Replacement of Ca++ but not other cations restored baseline conditions. In the presence of a clot, fibrin-selective plasminogen activation and clot lysis were triggered. Lysis was accompanied by less than 10% conversion of pro-UK (scu-PA) to two-chain UK, suggesting that the intrinsic activity of pro-UK (scu-PA) itself may have been responsible for fibrinolysis, although a contribution by the small amount of UK generated could not be excluded. Similarly, pro-UK (scu-PA) supported clot lysis for several days in the same plasma before the effect dissipated as a result of degradation to UK. When Glu-plasminogen in plasma was replaced by Lys-plasminogen, or when lysine was added to normal plasma, nonselective plasminogen activation and fibrinogenolysis occurred. It was concluded that under the experimental conditions, the fibrin specificity of pro-UK (scu-PA) can be explained by its selective activation of fibrin-bound plasminogen and is due to the latter's Lys-plasminogen-like conformation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3083889

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Thrombolytic therapy in acute myocardial infarction.

Authors:  U Priglinger; K Huber
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

Review 2.  Cardiovascular drugs.

Authors:  P Vermeij
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 3.  Use of plasminogen activators in venous thrombosis.

Authors:  J Hirsh; A G Turpie
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

Review 4.  Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.

Authors:  Rais Reskiawan A Kadir; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2019-09-24       Impact factor: 5.046

Review 5.  Modern treatment of pulmonary embolism.

Authors:  C M Kessler
Journal:  Lung       Date:  1990       Impact factor: 2.584

6.  Pharmacokinetics of C-1027 in mice as determined by TCA-RA method.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Mao-Jin Zhou; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

7.  Tissue distribution and excretion of 125I-lidamycin in mice and rats.

Authors:  You-Ping Liu; Quan-Sheng Li; Yu-Rong Huang; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

8.  Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.

Authors:  T A Hembrough; K R Kralovich; L Li; S L Gonias
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

Review 9.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 10.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.